Vaxcyte, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| PCVX | NVAX | BAVA.CO | LGND | VALN | 261780.KQ | |
|---|---|---|---|---|---|---|
| Market cap | 10.34B | 1.76B | 18.68B | 6.32B | 533.86M | 103.62B |
| P/E (TTM) | — | — | 12.8 | 127.0 | — | — |
| Forward P/E | -9.2 | -65.0 | 22.3 | 25.9 | 4.7 | — |
| Price/book | 3.2 | -9.2 | 1.4 | 6.6 | 5.9 | — |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +50.82% | +25.88% | +3.56% | +64.68% | −38.78% | +44.97% |
| Today | +8.01% | +10.02% | +1.46% | +0.83% | +2.18% | −2.90% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All PCVX news ›GPN Vaccines Raises $10 Million To Advance Gamma-PN Pneumococcal Vaccine Toward Phase 2 Trials
GPN Vaccines, a clinical-stage biotechnology company developing broadly protective bacterial vaccines, has closed a fully subscribed $10 million private placement with participation from new and existing investors. The financing will…
Full IDWeek Data Highlights 31-Valent Pneumococcal Conjugate Vaccine Candidate in Adults
VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial. In adults aged 50 years and older, all 28 serotypes shared with PCV20 and/or PCV21 met the noninferiority criterion, and all 4 unique and…
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026
BERKELEY HEIGHTS, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully... Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026…
Pneumococcal Vaccine Candidate Targeting 25 Serotypes Advances
— The vaccine showed a better immune effect than 20-valent vaccine against problematic serotype 3 WASHINGTON -- A pneumococcal conjugate vaccine (PCV) covering 25 serotypes was safe and generated immune responses among infants that were…
Vaxxinity (OTCMKTS:VAXX) Stock Price Breaks Above Two Hundred Day Moving Average – What’s Next?
Posted by Defense World Staff on Oct 27th, 2026 Vaxxinity, Inc. (OTCMKTS:VAXX – Get Free Report) shares crossed above its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $0.01 and…
Pfizer reports Phase II data for 25vPnC infant vaccine candidate
Pfizer has reported findings from a Phase II trial assessing PF-07872412 (25vPnC), its investigational 25-valent pneumococcal conjugate vaccine candidate, in infants. The results showed that a four-dose regimen provoked immune responses…
Pfizer Inc. Announces Detailed Results Across Serotypes From A Phase 2 Study For Its Investigational 25-Valent Pneumococcal Conjugate Vaccine Candidate PF-07872412 In Infants
Pfizer Inc. announced detailed results across serotypes from a Phase 2 study for its investigational 25-valent pneumococcal conjugate vaccine candidate, PF-07872412 , in infants. In the study, a... announced detailed results across…
Pfizer Says 25-Valent Pneumococcal Conjugate Vaccine Candidate Demonstrates 'Robust' Responses in Phase 2 Pediatric Study
Pfizer's investigational 25-valent pneumococcal conjugate vaccine candidate, PF-07872412, demonstrated robust immune responses against all 25 serotypes of invasive pneumococcal disease, of IPD, in... Pfizer Says 25-Valent Pneumococcal…
Pfizer's 25-Valent Pediatric Vaccine Shows Strong Phase 2 Data
These data support the ongoing Phase 3 development program for 25vPnC, which, if successful, could help provide protection against serotypes collectively responsible for approximately 84% of invasive pneumococcal disease (IPD) cases among…
Vaxart granted European patent covering oral norovirus vaccine through 2036
Vaxart (VXRT) announced that the European Patent Office formally published the grant of European Patent No. 3791859 effective August 26. This pa... Vaxart granted European patent covering oral norovirus vaccine through 2036 Vaxart (VXRT)…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- stocktitan.net26
- marketscreener.com13
- tradingview.com11
- investingnews.com4
- seekingalpha.com4
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 108 articles, not a forecast.